This episode explores the complex world of orphan drugs—medications developed for rare diseases that affect fewer than 200,000 people in the U.S.—through the story of Alexion Pharmaceuticals. Founded by two scientists who met in a grocery store ice cream aisle, Alexion shifted from pursuing treatments for common conditions to focusing exclusively on ultra-rare diseases after near collapse. Their breakthrough drug, Soliris (eculizumab), revolutionized treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH), a deadly blood disorder, dramatically improving patients' lives. However, the drug’s staggering cost—peaking at $440,000 per year—sparked intense ethical debate over pricing, access, and the sustainability of innovation in medicine. The narrative delves into the emotional and financial toll on patients and families, the pharmaceutical industry's need for profitability, and the broader implications of Alexion’s $39 billion acquisition by AstraZeneca. While Soliris transformed lives like that of former wrestler Joe Ellenberger, it also highlighted systemic challenges in balancing scientific progress with equitable access. The discussion raises urgent questions about healthcare policy, corporate responsibility, and the moral weight of assigning a price to life-saving therapies. Listeners are encouraged to engage with patient advocacy groups, stay informed, and advocate for policies that prioritize patient welfare over profit in the evolving landscape of rare disease treatment.